Close Menu

    All Patents held by Anthony Fauci

    11 Mins Read

    Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

    • Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin Patent number: 9896509 – Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    • Type: Grant Filed: August 3, 2016Date of Patent: February 20, 2018 Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
    • USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN Publication number: 20160333097 – Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    • Type: Application Filed: August 3, 2016Publication date: November 17, 2016 Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
    • Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin Patent number: 9441041 – Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
    • Type: Grant – Filed: September 21, 2015 – Date of Patent: September 13, 2016 – Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services – Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
    • USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN Publication number: 20160075786 – Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV
    • Type: Application – Filed: September 21, 2015 – Publication date: March 17, 2016 – Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Services – Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci
    • IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION Publication number: 20090285815 – Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
    • Type: Application – Filed: March 21, 2008 – Publication date: November 19, 2009 – Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
    • Fusion protein including of CD4 Patent number: 7368114 – Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.
    • Type: Grant – Filed: October 24, 2002 – Date of Patent: May 6, 2008 – Assignee: The United States of America as represented by the Department of Health and Human Services – Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
    • HIV related peptides Patent number: 6911527 – Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
    • Type: Grant – Filed: January 7, 2000 – Date of Patent: June 28, 2005 – Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services – Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci
    • Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4 Publication number: 20040265306 – Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
    • Type: Application – Filed: July 27, 2004 – Publication date: December 30, 2004 – Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci
    • Immunologic enhancement with intermittent interleukin-2 therapy Publication number: 20030180254 – Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    • Type: Application – Filed: January 23, 2003 – Publication date: September 25, 2003 – Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services – Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
    • Immunologic enhancement with intermittent interleukin-2 therapy Patent number: 6548055 – Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    • Type: Grant – Filed: August 9, 2000 – Date of Patent: April 15, 2003 – Assignee: The United States of America as represented by the Department of Health and Human Services – Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
    • Immunologic enhancement with intermittent interleukin-2 therapy Patent number: 6190656 – Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    • Type: Grant – Filed: September 2, 1997 – Date of Patent: February 20, 2001 – Assignee: The United States of America as represented by the Department of Health and Human Services – Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
    • Immunologic enhancement with intermittent interleukin-2 therapy – Patent number: 5696079 – Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.
    • Type: Grant – Filed: May 26, 1995 – Date of Patent: December 9, 1997 –Assignee: The United States of America as represented by the Department of Health and Human Services –Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
    Share.

    Related Posts